{
    "clinical_study": {
        "@rank": "30186", 
        "arm_group": {
            "arm_group_label": "MabThera/Rituxan", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This study will evaluate the efficacy and safety of intense combination treatment including\n      MabThera/Rituxan (rituximab), followed by MabThera/Rituxan maintenance therapy in patients\n      with B-cell CLL who are naive to chemotherapy. The anticipated time on study treatment is\n      2.5 years."
        }, 
        "brief_title": "CHAIROS Study A Study of MabThera/Rituxan (Rituximab) Maintenance Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Naive to Chemotherapy", 
        "completion_date": {
            "#text": "September 2012", 
            "@type": "Actual"
        }, 
        "condition": "Lymphocytic Leukemia, Chronic", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Lymphocytic, Chronic, B-Cell", 
                "Leukemia, Lymphoid", 
                "Chronic Disease"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients, >/= 18 years of age\n\n          -  B-cell CLL\n\n          -  No previous chemotherapy, radiotherapy, or immunotherapy\n\n        Exclusion Criteria:\n\n          -  Reduced organ function, or bone marrow dysfunction not due to CLL\n\n          -  Patients with a history of other malignancies within 2 years prior to study entry,\n             except for adequately treated cancer in situ of the cervix, or basal or squamous cell\n             skin cancer\n\n          -  Patients with a history of severe cardiac disease."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "43", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02013817", 
            "org_study_id": "ML18434"
        }, 
        "intervention": [
            {
                "arm_group_label": "MabThera/Rituxan", 
                "description": "Every 4 weeks for 6 cycles of induction, followed by maintenance therapy every 3 months x 8", 
                "intervention_name": "rituximab [MabThera/Rituxan]", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "MabThera/Rituxan", 
                "description": "Every 4 weeks, 6 cycles", 
                "intervention_name": "fludarabine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "MabThera/Rituxan", 
                "description": "Every 4 weeks, 3 cycles", 
                "intervention_name": "cyclophosphamide", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclophosphamide", 
                "Fludarabine monophosphate", 
                "Rituximab", 
                "Fludarabine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "February 3, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Innsbruck", 
                        "country": "Austria", 
                        "zip": "6020"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leoben", 
                        "country": "Austria", 
                        "zip": "8700"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Linz", 
                        "country": "Austria", 
                        "zip": "4010"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Linz", 
                        "country": "Austria", 
                        "zip": "4020"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rankweil", 
                        "country": "Austria", 
                        "zip": "6830"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salzburg", 
                        "country": "Austria", 
                        "zip": "5020"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wels", 
                        "country": "Austria", 
                        "zip": "4600"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Austria"
        }, 
        "number_of_arms": "1", 
        "official_title": "CHAIROS - Effect of Early Brief Intensification by Chemoimmunotherapy With FCR Followed by FR and Rituximab Maintenance on Clinical Response in Chemo-na\u00efve Patients With B-CLL", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Austria: Federal Ministry of Health and Women"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Complete response rate", 
            "safety_issue": "No", 
            "time_frame": "approximately 2.5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02013817"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Response rate: complete response (CR), partial response (PR) and nodal partial response (nPR)", 
                "safety_issue": "No", 
                "time_frame": "approximately 2.5 years"
            }, 
            {
                "measure": "Time to next treatment", 
                "safety_issue": "No", 
                "time_frame": "approximately 5.5 years"
            }, 
            {
                "measure": "Molecular complete response", 
                "safety_issue": "No", 
                "time_frame": "approximately 2.5 years"
            }, 
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "approximately 5.5 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2005", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}